CRBN Knockout Cell Line (Hela)

The choice depends on whether you are studying CRBN (cereblon)'s role as the substrate receptor of the CRL4^CRBN E3 ubiquitin ligase or modeling the foundational platform for IMiD drugs and molecular glue degraders — CRBN is one of the most clinically validated cancer drug targets and the original molecular glue degrader receptor. The Knockout line is the gold-standard tool for asking whether CRBN is required for these processes — CRBN is a CUL4-RING E3 ligase substrate receptor (with DDB1, CUL4A, RBX1 forming CRL4^CRBN) that was identified as the molecular target of thalidomide (the cause of historical birth defects); structural studies revealed that thalidomide and its analogs (IMiDs: lenalidomide, pomalidomide) bind CRBN and recruit neo-substrates (IKZF1, IKZF3, CK1α, GSPT1) for polyubiquitination and proteasomal degradation. This is the prototypical 'molecular glue' mechanism. Overexpression is useful for studying CRBN in heterologous expression contexts. For targeted protein degradation research, the EDITGENE CRBN Knockout in HeLa is uniquely valuable — CRBN is the foundational and most clinically validated target of the entire molecular glue and PROTAC field. Rescue with wild-type or thalidomide-binding-pocket mutant (Y355A, W380A — the critical thalidomide-binding tri-tryptophan pocket; or Y386A — Y384 in some numbering) CRBN enables systematic IMiD/molecular glue/PROTAC specificity testing. The knockout is a critical specificity control for ⭐⭐⭐ thalidomide (Thalomid), ⭐⭐⭐ lenalidomide (Revlimid, top-selling multiple myeloma drug), ⭐⭐⭐ pomalidomide (Pomalyst), iberdomide (Iberlumate/CC-220), mezigdomide (CC-92480), CC-90009 (GSPT1 degrader), and the entire class of CRBN-recruiting PROTACs (ARV-110/bavdegalutamide for prostate cancer, ARV-471/vepdegestrant for ER+ breast cancer, KT-474 for IRAK4 in atopic dermatitis/hidradenitis suppurativa, NX-2127 for BTK). CRBN-recruiting molecular glue degraders and PROTACs constitute one of the most rapidly growing classes of cancer drugs.

Primary applications: • IMiD specificity (foundational class): critical genetic control for ⭐⭐⭐ thalidomide, lenalidomide (Revlimid), pomalidomide (Pomalyst), iberdomide (CC-220), and mezigdomide (CC-92480) — these IMiDs should have no degrader activity in CRBN-null cells. • Molecular glue degrader specificity: critical genetic control for CC-90009 (GSPT1 degrader), CC-885 (preclinical GSPT1 degrader), and emerging CRBN-recruiting molecular glues. • CRBN-recruiting PROTAC specificity: critical genetic control for ARV-110/bavdegalutamide (AR degrader for mCRPC), ARV-471/vepdegestrant (ER degrader for ER+ breast cancer), KT-474 (IRAK4 degrader), NX-2127 (BTK degrader), DT2216 (BCL-XL degrader), and the rapidly growing CRBN-PROTAC pipeline. • Neo-substrate degradation studies: IKZF1, IKZF3, CK1α, GSPT1 protein stability in CRBN-null versus rescued cells with IMiD treatment. • Resistance mechanism studies: rescue with Y355A, W380A thalidomide-binding pocket mutants for understanding IMiD resistance mechanisms (CRBN domain mutations are a major cause of clinical IMiD resistance in multiple myeloma). EDITGENE recommends this model as the gold-standard genetic specificity control for the entire IMiD, molecular glue degrader, and CRBN-recruiting PROTAC therapeutic field — CRBN is one of the most clinically validated drug targets in oncology.

Yes, and rescue experiments are uniquely powerful for IMiD/molecular glue/PROTAC research: • Construct design: use a codon-modified CRBN sequence with a small C-terminal tag (FLAG, HA). CRBN has N-terminal Lon protease-like domain, helical-bundle domain (HBD), and C-terminal thalidomide-binding domain (TBD) with the critical tri-tryptophan pocket (W380, W386, W400, plus Y355) — preserve all elements. • Thalidomide-binding-pocket mutant rescue: ⭐⭐ Y355A, W380A, W386A, W400A mutations in the tri-tryptophan/Y-pocket abolish IMiD binding and serve as the gold-standard specificity control — these mutations distinguish CRBN-dependent from CRBN-independent compound activities. • IMiD resistance mutation rescue: rescue with patient-derived CRBN mutations from IMiD-resistant multiple myeloma (e.g., A395, Y384 missense, frameshift mutations) for clinical resistance mechanism studies. • DDB1-binding-deficient rescue: N-terminal CRBN mutations disrupt CRL4 complex assembly. • Functional readout: rescue should restore IKZF1, IKZF3, CK1α degradation upon lenalidomide treatment; thalidomide-binding-pocket mutants should be insensitive to all IMiDs and CRBN-recruiting molecular glues. HeLa transduces efficiently with lentivirus and supports systematic CRBN mutation analysis for the entire CRBN-targeted therapeutic field — this is one of the most important genetic tools in modern cancer drug development.